ADPT Adaptive Biotechnologies
- 2.600
- -0.010-0.38%
- 2.599
- -0.001-0.05%
Adaptive Biotechnologies News
Netflix, ON Semiconductor And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Nasdaq futures declining over 100 points on Friday.Shares of Netflix, Inc. (NASDAQ:NFLX) fell sharply in today's pre-market trading following first
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Wang & Lee Group, Inc. (NASDAQ:WLGS) rose sharply in today's pre-market trading after the company reported a year-over-year increase in FY23 financial results.Wang & Lee Group posted a FY23
Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
SEATTLE, April 17, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of The Travelers Companies, Inc. (NYSE:TRV) fell sharply during Wednesday's session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' e
Adaptive Biotechnologies Names Kyle Piskel New CFO
BTIG Sticks to Their Buy Rating for Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock's 33% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares are down a considerable 33% in the last month, which continues a horrid run for the company.
Express News | BTIG Maintains Buy on Adaptive Biotechnologies, Lowers Price Target to $5
Adaptive Biotechnologies Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/04/2024 79.53% BTIG $6 → $5 Maintains Buy 02/16/2024 79.53% Goldman Sachs $11 → $5 Maintains Neutral 02
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX) and Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies Names New CFO Preserves Strong Capital Position
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) announced Tuesday, April 3, that after a strategic review, the company will operate two businesses — Minimal Residual Disease (MRD) and Immune Medici
Express News | Adaptive Biotechnologies Shares Are Trading Lower. The Company Yesterday Provided a Strategic Review and Announced Preliminary Q1 2024 Revenue
J.P. Morgan Sticks to Its Buy Rating for Adaptive Biotechnologies (ADPT)
Adaptive Biotechnologies Reports Preliminary Q1 Revenue, Appoints Kyle Piskel as CFO
Adaptive Biotechnologies (ADPT) reported Tuesday that preliminary Q1 total revenue rose about 12% to $41 million to $43 million from a year earlier. Analysts polled by Capital IQ expect $38.2 million.
Adaptive Biotechnologies to Restructure Businesses After Review
By Ben Glickman Adaptive Biotechnologies said it had opted to restructure its MRD and Immune Medicine businesses after a strategic review. The Seattle-based company also said Tuesday that Chief Fina
Adaptive Biotechnologies CFO Resigns, Successor Appointed
Express News | Adaptive Biotechnologies Tycho Peterson, Chief Financial Officer Will Be Departing The Company To Pursue Another Opportunity. Kyle Piske Will Succeed Tycho As Full-time CFO
Adaptive Biotechnologies: Review Finds Best Outcome for Shareholder Value Is to Operate MRD and Immune Medicine Businesses Internally >ADPT
Adaptive Biotechnologies: Review Finds Best Outcome for Shareholder Value Is to Operate MRD and Immune Medicine Businesses Internally >ADPT
Adaptive Biotechnologies Sees 1Q Rev $41M-$43M >ADPT
Adaptive Biotechnologies Sees 1Q Rev $41M-$43M >ADPT
Adaptive Biotechnologies CFO Tycho Peterson to Leave Co to Pursue Another Opportunity >ADPT
Adaptive Biotechnologies CFO Tycho Peterson to Leave Co to Pursue Another Opportunity >ADPT
Analysis
Price Target
No Data
